MAPT and Alzheimer disease: The ongoing advancement section was further categorized into monoclonal antibodies, tau and amyloid-targeting treatments, anti-neuroinflammation, antidiabetic, and miscellaneous drugs, phase 2 trials of anti-inflammatory agents, and AD-associated symptom treatments.